Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | TKT | P29401 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27088681 | 1.00 | PDCD1LG2 (0.39) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL27089257 | 1.00 | PDCD1LG2 (0.39) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL31382734 | 0.98 | PDCD1LG2 (0.38) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL31242986 | 0.88 | NOS3 (0.36) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL29322201 | 0.83 | PDCD1LG2 (0.40) | PDCD1LG2CD274ADRB2ALDH1A1LMNA | |
| SCHEMBL31171578 | 0.82 | NOS2 (0.41) | NOS3NOS1NOS2ADRB2NAPRT | |
| SCHEMBL31298224 | 0.82 | NOS2 (0.41) | NOS3NOS1NOS2ADRB2NAPRT | |
| SCHEMBL31171591 | 0.81 | NOS3 (0.35) | NOS3NOS1NOS2ADRB2ALDH1A1 | |
| SCHEMBL31382782 | 0.79 | SHMT2 (0.35) | NOS3NOS1NOS2NAPRTTKT | |
| SCHEMBL32666265 | 0.79 | SHMT2 (0.35) | NOS3NOS1NOS2NAPRTTKT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735451-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | Kumquat Biosciences Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025007000-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024083168-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | HRAS, KRAS, BCL6 | PDCD1LG2 3311/4885CD274 4361/4885NOS3 4056/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | PDCD1LG2 388/4885CD274 775/4885NOS3 3905/4885 |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | PDCD1LG2 809/4885CD274 1133/4885NOS3 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.